Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$26.98 USD
-0.95 (-3.40%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $26.99 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
Arcturus Therapeutics Holdings Inc. [ARCT]
Reports for Purchase
Showing records 1 - 20 ( 140 total )
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Bivalent Kostaive Was Non-Inferior vs. Comirnaty; Data Support Updated Kostaive For 2H24 Launch in Japan
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap; Kostaive Launch in Japan is Expected in 2H24 By Meiji; Cash Runway Further Extended to 1Q27; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 25.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
ARCT-154 Shows Superior Duration of Immune Response in Six-Month Follow-up Analysis in Japan, Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Lancet Publication Highlights ARCT-154''s Efficacy Versus Comirnaty That Underpins Its Approval in Japan; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
FDA Grants Orphan Drug Designation For ARCT-032 in Cystic Fibrosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
ARCT-154 Approved in Japan As Both a Primary Immunization and Booster For COVID-19; Increasing PT to $60; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ARCT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Price: 12.50
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; ARCT-154''s Approval in Japan On Target By YE2023; Multiple Near-Term Readouts From Other Programs; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Arcturus Extends Agreement With CF Foundation; Secures $25M in Funding For ARCT-032''s Development; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Presentation at ESWI Influenza Conference Highlights Durable Effects of Arcturus'' sa-MRNA COVID-19 Vaccines; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
MAA Accepted in Europe For ARCT-154 as COVID-19 Vaccine and Booster; Approval in Japan Expected in 2023; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
JV Partner Awarded $115M in Grants to Build mRNA Factory in Japan; Potential ARCT-154 Approval as Early as October
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap; ARCT-154''s Approval in Japan On Target in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
ARCT-154 Shows Non-Inferiority vs.COMIRNATY and Superiority in Omicron Variant As COVID-19 Vaccine Booster; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
ARCT-154 Could Enter the Japanese Market as COVID-19 Primary Vaccine Course and as a Booster Dose in 2023; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
ARCT-810 Granted Fast Track Designation For OTC Deficiency; Key Catalyst Is ARCT-154 COVID-19 Vaccine Data; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap: Expecting ARCT-154 Approval in Japan As COVID-19 Vaccine and Booster in 2023; Upgrade to Buy With $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
NDA Filed in Japan For ARCT-154 As COVID-19 Primary Immunization; We Await ARCT-810 OTC Data; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap; With Vaccine Programs Out-licensed to CSL, Arcturus Turns Focus to Rare Disease Programs; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap: Priority Shifts Back to OTC, CF Programs; CSL Takes COVID-19, Funds BARDA Contract; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50